Biomea Fusion reports Phase 1 results for oral GLP — 1 drug BMF — 650 showing up to 3.2% weight loss at Day 29
Biomea Fusion reported Phase 1 results for oral GLP-1 drug candidate BMF-650, showing early signs of weight loss activity. Outcomes pointed to consistent short-term weight reduction versus placebo, without detailing specific efficacy measurements. Tolerability looked manageable, with no severe safety events reported in